Borderline tumors of the ovary - A systematic review;Borderline-tumoren des ovars - Eine systematische übersicht

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 9, 2009, Pages 807-833

  Bois, A Du ^a   Ewald Riegler, N ^a   Bois, O Du ^a   Harter, P ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Borderline tumors; Low malignant potential; Outcome; Prognostic factors

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CLOMIFENE; GESTAGEN; GONADOTROPIN; TUMOR MARKER;

BORDERLINE OVARY TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CONSERVATIVE TREATMENT; DATA EXTRACTION; DIFFERENTIAL DIAGNOSIS; FERTILIZATION IN VITRO; GENE EXPRESSION; GENE MUTATION; HUMAN; LAPAROSCOPY; LAPAROTOMY; LYMPHADENECTOMY; MISMATCH REPAIR; MOLECULAR GENETICS; ONCOGENE; OPERATION DURATION; OUTCOME ASSESSMENT; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; OVARY TUMOR; OVULATION INDUCTION; PATIENT COUNSELING; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; REOPERATION; REVIEW; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; STRUCTURED QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 70449573033     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1186007     Document Type: Review

References (215)

1. Taylor Jr. HC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929; 48: 204-230
2. Seidman JD, Soslow RA, Vang R et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004; 35: 918-933
3. Bell DA, Longacre TA, Prat J et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 2004; 35: 934-948
4. Silverberg SG, Bell DA, Kurman RJ et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 2004; 35: 910-917
5. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31: 539-557
6. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Human Pathol 1990; 21: 397-403
7. Sherman ME, Mink PJ, Curtis R et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: A population-based Analysis. Cancer 2004; 100: 1045-1052
8. Cusido M, Balaguero L, Hernandez G et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol 2007; 104: 617-622
9. Akeson M, Zetterqvist BM, Dahllops K et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer 2008; 18: 453-459
10. Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. Cancer 1993; 71: 1810-1820
11. Park J-Y, Kim D-Y, Kim J-H et al. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol 2009; 10.1016/2008:12034
12. Fauvet R, Boccara J, Dufournet C et al. Laparoscopic management of borderline ovarian tumors: results of a French multi center study. Ann Oncol 2005; 16:403-410
13. Zanetta G, Rota S, Chiari S et al. Behaviour of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19: 2658-2664
14. Trope C, Kaern J, Vergote IB et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 51: 236-243
15. Longacre TA, McKenney JK, Tazelaar HD et al. Ovarian tumors of low malignant potential (borderline tumors). Am J Surg Pathol 2005; 29: 707-723
16. Ren J, Peng Z, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol Oncol 2008; 110: 162-167
17. Leake JF, Currie JL, Rosenshein NB et al. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47: 150-158
18. Morice P, Camatte S, El Hassan J et al. Clinical outcome and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75: 92-96
19. De Iaco P, Ferrero A, Rosati F et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol 2008; 10.1016/j.ejso.2008.09.011
20. Buttin B, Herzog TJ, Powell MA et al. Epithelial ovarian tumors of low malignant potential: The role of microinvasion. Obstet Gyneccol 2002; 99: 11-17 (Pubitemid 34075461)
21. Romangnolo C, Gadducci A, Sartori E et al. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecol Oncol 2006;101:255-260
22. Bostwick DG, Tazelaar HD, Ballon SC et al. Ovarian epithelial tumors of borderline malignancy. Cancer 1986; 58: 2052-2065
23. Prat J, de Nictolis M. Serous borderline tumors of the ovary: A long- term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Pathol 2002; 26: 1111-1128
24. Yokoyama Y, Moriya T, Takano T et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 2006; 94: 1586-1591
25. Kuoppala T, Heinola M, Aine R et al. Serous and mucinous borderline tumors of the ovary: A clinicopathologic and DNA-ploidy study of 102 cases. Int J Gynecol Cancer 1996; 6: 302-308
26. Chambers JT, Merino MJ, Kohorn EI et al. Borderline ovarian tumors. Am J Obstet Gynecol 1988; 159: 1088-1094
27. Winter WE, Kucera PR, Rodgers W et al. Surgical staging in patients with tumors of low malignant potential. Obstet Gynecol 2002; 100: 671-676
28. Liapis A, Bakalianou K, Iavazzo C et al. A retrospective analysis of borderline ovarian tumors in a Greek university hospital. Eur J Gynecol Oncol 2008; 29: 383-385
29. Gotlieb WH, Flikker S, Davidson B et al. Borderline tumors of the ovary. Cancer 1998; 82: 141-146
30. Rice LW, Berkowitz RS, Mark SD et al. Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol1990; 39: 195-198
31. Papadimitriou DS, Martin-Hirsch P, Kitchener HC et al. Recurrent borderline ovarian tumors after conservative management in women wishing to retain their fertility. Eur J Gynecol Oncol 1999; 20: 94-97
32. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): A long follow-up study, including patients with microinvasion, lymph node metastasis and transformation to invasive serous carcinoma. Cancer 1996; 78: 278-286
33. Kliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol 1986; 68: 338-344
34. Donnez J, Munschke A, Berliers M et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003; 79: 1216-1221
35. Tasker M, Langley FA. The outlook for women with borderline epithelial tumours of the ovary. BJOG 1985; 92: 969-973
36. Nakashima N, Nagasaka T, Oiwa N et al. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 1990; 38: 90-98
37. Kumpulainen S, Kuoppala T, Leminen A et al. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. Acta Obstet Gynecol 2007; 86: 610-614
38. Nation JG, Krepart GV. Ovarian carcinoma of low malignant potential: staging and treatment. Am J Obstet Gynecol 1986; 154: 290-293
39. Julian CG, Woodruff D. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40: 860-867
40. Maneo A, Vignali M, Chiari S et al. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 2004; 94: 387-392
41. Boran N, Cil AP, Tulunay G et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005; 97: 845-851
42. Guerrieri C, Hogberg T, Wingren S et al. Mucinous borderline and malignant tumors of the ovary. Cancer 1994; 74: 2329-2340
43. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): A reevaluation of the concept of stromal microinvasion. Am J Surg Path 2006; 30: 1209-1221
44. Pirimoglu ZM, Afsin Y, Guzelmeric K,Yilmaz M et al. Is it necessary to do retroperitoneal evaluation in borderline epithelial ovarian tumors. Arch Gynecol Obstet 2008; 277: 411-414
45. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary. A clinicopathologic analysis of 135 cases. Am J Surg Pathol 2003; 27: 725-736
46. Allison KH, Swisher EM, Kerkering KM et al. Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: When is a full staging procedure unnecessary? Int J Gynecol Path 2007; 27: 10-17
47. Katzenstein ALA, Mazur MT, Morgan TE et al. Proliferative serous tumors of the ovary. Am J Surg Pathol 1978; 5: 339-355
48. Bristow RE, Gossett DR, Shook DR et al. Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome. Gynecol Oncol 2002; 86: 163-170
49. Fort MG, Pierce VK, Saigo PE et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32: 269-272
50. Hogg R, Scurry J, Kim S-N et al. Microinvasion links ovarian serous borderline tumor and grade I invasive carcinoma. Gynecol Oncol 2007; 106: 44-51
51. Engelen MJA, de Bruijn HWA, Hollema H et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 2000; 78: 16-20
52. Morris RT, Gershenson DM, Silva EG et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 2000; 95: 541-547
53. Camatte S, Morice P, Atallah D et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: An analysis of a series of 42 lymphadenectomies. J Am Coll Surg 2002; 195: 332-338
54. Casey AC, Bell DA, Lage JM et al. Epithelial ovarian tumors of borderline malignancy: Long-term follow-up. Gynecol Oncol 1993; 50: 316-322
55. Rao GG, Skinner EN, Gehring PA et al. Fertility-sparing surgergy for ovarian low malignant potential tumors. Gynecol Onkol 2005; 98: 263-266
56. Betash N, Modares M, Abolhasani M et al. Borderline ovarian tumours: clinical analysis of 38 cases. J Obstet Gynaecol 2004; 24: 157-160
57. Lim-Tan SK, Cajigas HE, Sculy RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988; 72: 775-781
58. Leake JF, Rader JS, Woodruff JD et al. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991; 42: 124-130
59. Massad LS, Hunter VJ, Szpak CA et al. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol 1991; 78: 1027-1031
60. Demeter A, Csapó Z, Szánthó A et al. A retrospective study of 27 ovarian tumors of low malignant potential. Eur J Gynaecol Oncol 2002; 23:415-418
61. Darai E, Teboul J, Fauconnier A et al. Management and outcome of borderline ovarian tumors incidentally discovered at or after laparoscopy. Acta ObstetGynecol Scand 1998; 77: 451-457
62. Chan JK, Lin YG, Loizzi V et al. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003; 48: 756-760
63. Laurent I, Uzan C, Gouy S et al. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern. Ann Surg Oncol 2008; 15: 3561-3566
64. Shappell HW, Riopel MA, Smith Sehdev AE et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors. Am J Surg Path 2002; 26: 1529-1541
65. O'Quinn AG, Hannigan EV. Epithelial ovarian neoplasms of low malignant potential. Gynecol Oncol 1985; 21: 177-185
66. Nezhat FR, Ezzati M, Chuang L et al. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol 2009; 200: 83.e1-83.e6
67. Morice P, Camatte S, ReyA et al. Prognostic factors for patients with advanced stage serous borderline tumors of the ovary. Ann Oncol 2003; 14: 592-598
68. Silva EG, Gershenson DM, Malpica A et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninva- sive implants is time dependent. Am J Surg Pathol 2006; 30: 1367-1371
69. Gershenson DM, Silva EG, Tortolero-Luna G et al. Serous borderline tumors of ovarian with noninvasive peritoneal implants. Cancer 1998; 83:2157-2163
70. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Cancer 1988; 62: 2212-2222
71. Gershenson DM, Silva EG, Levy L et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998; 82: 1096-1103
72. Barakat RR, Benjamin I, Lewis Jr. JL et al. Platinum-based chemotherapy for advanced-stage ovarian carcinoma malignant potential. Gynecol Oncol 1995; 59: 390-393
73. Camatte S, Morice P, Pautier P et al. Fertility results after conservative treatment of advanced stage serous borderline tumor of the ovary. BJOG2002; 109: 376-380
74. Lackmann F, Carey MS, Kirk ME et al. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecol Oncol 2003; 90: 407-412
75. Vandeput I, Amant F, Vergote I. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy. Gynecol Oncol 2005; 98: 523 (letter)
76. Deffieux X, Morice P, Camatte S et al. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol 2005; 97: 84-89
77. Nijman HW, Burger CW, Baak JPA et al. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 1992; 28A: 1971-1973
78. Barnhill DR, Kurman RJ, Brady MF et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: A Gynecologic Oncology Group Study. J Clin Oncol 1995; 13: 2752-2756
79. Desfeux P, Camatte S, Chatellier G et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005; 98: 390-395
80. Odegaard E, Staff AC, Langebrekke A et al. Surgery of borderline tumors of the ovary; retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol 2007; 86: 620-626
81. Camatte S, Morice P, Thoury A et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 2004; 40: 1842-1849
82. Ji H, Yliskoski M, Anttila M et al. Management of stage-I borderline ovarian tumors. Int J Gynecol Oncol 1996; 54: 37-44
83. Tazelaar HD, Bostwick DG, Ballon SC et al. Conservative treatment of borderline ovarian tumors. Obstet Gynecol 1985; 66: 417-422
84. Creasman WT, Park R, Norris H et al. Stage I borderline ovarian tumors. ObstetGynecol 1982; 59: 93-96
85. Tinelli FG, Tinelli R, La Grotta F et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta ObstetGynecol 2007; 86: 81-87
86. Marcickiewicz J, Brannstrom M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence, Acta Obstet Gynecol 2006; 85: 1496-1500
87. Seracchioli R, Venturoli S, Colombo FM et al. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril 2001; 76: 999-1004
88. Fasouliotis SJ, Davis O, Schattman G et al. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report. Fertil Steril 2004; 82: 568-572
89. Skirnisdottir I, Garmo H, Wilander E et al. Borderline ovarian tumors in Sweden 1960-2005: Trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008; 123: 1897-1901
90. Iscovich J, Shushan A, Schenker JG et al. The incidence of borderline ovarian tumors in Israel. A population-based study. Cancer 1998; 82: 147-151 (Pubitemid 28070491)
91. Levi F, La Vecchia C, Randimbison L et al. Borderline ovarian tumors in Vaud, Switzerland: Incidence, survival and second neoplasms. Br J Cancer 1999; 79: 4-6
92. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States: Results from the SEER program, 1978-1998. Cancer 2002; 95: 2380-2389
93. Heintz APM, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. In: Pecorelli S, ed. 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 2006; 95 (Suppl. 1): 161-192
94. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807-2816
95. Gotlieb WH, Chetrit A, Menczer Jet al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005; 97: 780-783
96. Gram IT, Braaten T, Adami H-O et al. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer. Int J Cancer 2008; 122:647-652
97. JordanSJ, GreenAC, Whiteman DC et al., for the Australian CancerStudy (Ovarian Cancer), and the Australian Ovarian Cancer Study Group. Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum. Gynecol Oncol 2007; 107: 223-230
98. Collaborative Group of Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives; collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87303 controls. Lancet 2008; 371: 303-314
99. Ness RB, Cramer DW, Goodmann MT et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2002; 155: 217-224
100. Zreik TG, Ayoub CM, Hannoun A et al. Fertility drugs and risk of ovarian cancer: Dispelling the myth. Curr Opin Obstst Gynecol 2008; 20:313-319
101. Rossing MA, Tang MTC, Flagg EW et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160: 1070-1078
102. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor. A review. Placenta 2008; 29: S169-S177
103. Parazzini F, Negri E, La Vecchia C et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 1998; 68: 226-228
104. Rossing MA, Daling JR, Weiss NS et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331: 771-776
105. Jensen A, Sharif H, Frederiksen K et al. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ 2009; 338: b249, 10.1136/bmj.b249
106. Venn A, Watson L, Bruinsma F et al. Risk of cancer after use of fertility drugs with in-vitro fertilization. Lancet 1999; 354: 1586-1590
107. Landen Jr. CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005
108. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26:1-10
109. Kurman RJ, Visvanathan K, Roden R et al. Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198: 351-356
110. Kurman RJ, Shih I-M. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-160
111. Olsen CM, Green AC, Nagle CM et al. Epithelial ovarian cancer: testing the "androgen hypothesis". Endocrine-Related Cancer 2008; 15: 1061-1068
112. Berchuck A, Heron KA, Carney ME et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4: 2433-2437
113. Merajver SD, Pham TM, Caduff RF et al. Somatic mutations in the BRCA1 gene in sporadicovarian tumors. Nat Genet1995; 9: 439-443
114. Thrall M, Gallion HH, Kryscio R et al. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. IntJ Gynecol Cancer 2006; 16: 166-171
115. Zheng W, Luo F, Lu JJ et al. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol 2000; 76: 294-300
116. Russel PA, Pharoah PD, De Foy K et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 2000; 87: 317-321
117. Wang C. Expression of BRCA1 protein in benign borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.JPathol 2004; 202: 215-223
118. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am JObstetGynecol 2008; 198: 459.e1-459.e9
119. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinoma of varying grade and malignant potential. Oncogene 2005; 24: 1053-1065
120. Bonome T, Lee JY, Park DC et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65:10602-10612
121. Gershenson DM, Wong KK. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Educational Book. Am Soc Clinical Oncol 2007: 313-317
122. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophy- lactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456
123. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. JPathol 2007; 211: 26-35
124. Jarboe E, Folkins A, Nucci MR et al. Serous carcinogenesis in the fallopian tube: A descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9
125. Palomba S, Zupi E, Russo T et al. Comparison of two fertility-sparing approaches for bilateral borderline tumours: a randomized controlled study. Human Rep 2007; 22: 578-585
126. Chang S-J, Ryu H-S, Chang K-H et al.Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol 2008; 87: 478-481
127. Kaern J, Trope CG, Kristensen GB et al. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3: 349-358
128. Lai C-H, Hsueh S, Chang T-C et al.The role of DNA flow cytometry in borderline malignant ovarian tumors. Cancer 1996; 78: 794-802
129. Meyer JS, Gersell DJ, Yim SY. Cell proliferation in ovarian carcinoma: Superior accuracy of S-phase fraction (SPF) by DNA labelling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate. Gynecol Oncol 2001; 81: 466-476
130. Verbruggen MB, van Diest PJ, Baak JP et al. The prognostic and clinical value of morphometric and DNA cytometry in borderline ovarian tumors: a prospective study. Int J Gynecol Pathol 2009; 28: 35-40
131. Snider DD, Stuart GCE, Nation JG et al. Evaluation of surgical staging in stage I low malignant potential ovarian tumors. Gynecol Oncol 1991; 40: 129-132
132. Fortin A, Morice P, Thoury A et al. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenterstudy. Fertil Steril 2007; 87: 591-596
133. Brun J-L, Cortez A, Rouzier R et al. Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors. Am J Obstet Gynecol 2006; 199: 244.e1-244.e7
134. Attanucci CA, Ball HG, Zweizig SL et al. Differences in symptoms between patients with benign and malignant ovarian neoplasms. Am J Obstet Gynecol 2004; 190: 1435-1437
135. Vine MF, Calingaert B, Berchuck A et al. Characterization of prediag- nostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol 2003; 90: 75-82
136. Vine M, Ness RB, Calingaert B et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 2001; 83: 466-471
137. Webb PM, Purdie DM, Grover S et al. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004; 92: 232-239
138. Economou A, Panagopoulos P, Koutras I et al. A retrospective study of 32 borderline ovarian tumors: The experience of a non-specialized centre. Eur J Gynaecol Oncol 2005; 26: 196-198
139. DeSouza NM, O'Neill R, McIndoe GA et al. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. AJR 2005; 184: 999-1003
140. Yazigi R, Sandstad J, Munoz AK. Primary staging in ovarian tumors of low malignant potential. Gynecol Oncol 1988; 31: 402-408
141. Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981; 12: 107-119
142. Eltabbakh GH, Yadev PR, Morgan A. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 1999; 75: 476-479
143. Sykes PH, Quinn MA, Rome RM. Ovarian tumors of low malignant potential: A retrospective study of 234 patients. Int Gynecol Cancer 1997; 7: 218-226
144. Tamakoshi K, Kikkawa F, Shibata K et al. Clinical value of CA 125, CA 19-9, CEA, CA 72-4 and TPA in borderline ovarian tumor. Gynecol Oncol 1996; 62: 67-72
145. Schutter EM-J, Davelaar EM, van Kamp GJ et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002; 187: 385-392
146. Gotlieb WH, Soriano D, Achiron R et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol 2000;183:541-546
147. Benedet JL, Bender H, Jones III H et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209-262
148. du Bois A, Burges A, Emons G et al. In: Schmalfeldt B, Pfisterer J, Hrsg. Interdisziplinäre S2 k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren 2007, Kommission Ovar der AGO e.V. München: W. Zuckschwerdt Verlag; 2007
149. Cadron I, Leunen K, van Gorp T et al. Management of borderline neoplasms. J Clin Oncol 2007; 25: 2928-2937
150. Verleye L, Ottevanger PB, van der Graaf W et al. EORTC-GCG process quality indicators for ovarian cancer surgery. Gynaecological Cancer Group (GCG) of European Organisation for Research and Treatment of Cancer (EORTC). EurJ Cancer 2009; 45: 517-526
151. du Bois A, Rochon J, Pfisterer J et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review. Gynecol Oncol 2008; 112: 422-436
152. Lin PS, Gershenson DM, Bevers MW et al. The current status of surgical staging of ovarian serous borderline tumors. Cancer 1999; 85: 905-911
153. Menzin AW, Gal D, Lovecchio JL. Contemporary surgical management of borderline ovarian tumors: A survey of the society of gynecologic oncologists. Gynecol Oncol 2000; 78: 7-9
154. Olsen CM, Green AC, Nagle CM et al. Epithelial ovarian cancer: testing the "androgen hypothesis". Endocrine-Related Cancer 2008; 15: 1061-1068
155. Di Re F, Paladini D, Fontanelli R et al. Surgical staging for epithelial ovarian tumors of low malignant potential. Int J Gynecol Cancer 1994; 4: 310-314
156. McKenney JK, Balzer JK, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Am J Surg Path 2006; 30: 614-624
157. Wingo SN, Knowles LM, Carrick KS et al. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. Am J Obstet Gynecol 2006; 194: 20-22
158. Tempfer CB, Polterauer S, Bentz E-K et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: A retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 2007; 107: 248-252
159. Wasinghon P, Suthhippintawong C, Tuipae S. The accuracy of intraoperative frozen sections in the diagnosis of ovarian tumors. J Med Assoc Thai 2008; 91: 1791-1795
160. Rakhshan A, Zham H, Kazempour M. Accuracy of frozen section diagnosis in ovarian masses: experience at a tertiary oncology center. Arch Gynecol Obstet 2008; online first: 10.1007/s00404-008- 0899-906
161. Yarandi F, Eftekhar Z, Izadi-Mod N et al. Accuracy of intraoperative frozen section in the diagnosis of ovarian tumors. Aus NZ J Obstet Gynecol 2008; 48: 438-441
162. Twaalfhoven FCM, Peters AAW, Trimbos JB et al. The accuracy of frozen section diagnosis of ovarian tumors. Gynecol Oncol 1991; 41: 189-192
163. Rose PG, Rubin RB, Nelson BE et al. Accuracy of frozen-section (intraoperative consultation) diagnosis of ovarian tumors. Am J Obstet Gynecol 1994; 171:823-826
164. Yeo EL, Yu KM, Poddar NC et al. The accuracy of intraoperative frozen section in the diagnosis of ovarian tumors. J Obstet Gynaecol Res 1998; 24: 189-195
165. PintoPBC,AndradeALA,DerchainSFM.Accuracyofintraoperativefro- zen section diagnosis of ovarian tumors. Gynecol Oncol 2001; 81: 230-232
166. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemo- Therapyin Ovarian Neoplasm trial. JNatl CancerInst2003; 95: 113-125
167. Zanetta G, Rota S, Chiari Set al. The accuracy ofstaging: an important prognostic determinator in stage I ovarian carcinoma. Ann Oncol 1998; 9: 1097-1101
168. Torrent Colomer A, Martin Jiminez A, Bover Barcelo MI. Laparoscopic treatment and staging of early ovarian cancer. J Minimal Inv Gyn 2008; 15: 414-419
169. Hopkins MP, Morley GW. Thesecond-lookoperationandsurgicalreex- ploration in ovarian tumor of low malignant potential. Obstet Gynecol 1989; 74: 375-378
170. Darai E, Tulpin L, Prugnolle H et al. Laparoscopic restaging of borderline ovarian tumors. Surg Endosc 2007; 21: 2039-2043
171. Fauvet R, Boccara J, Dufournet C et al. Restaging surgery for women withborderlineovarian tumors. Cancer2004; 100: 1145-1151
172. Querleu D, Papageorgiou T, Lambaudie E et al. Laparoscopic restaging of borderline ovarian tumours: results of 30 cases initially presumed as stage IA borderline ovarian tumours. BJOG 2003; 110: 201-204
173. Gershenson DM. Clinical management potential tumors of low malignancy. Best Pract Res Clin Obstet Gynecol 2002; 16/4: 513-527
174. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: Are they ever malignant? Inter J Gynecol Pathol 1993; 12: 120-127
175. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006; 103: 841-847
176. Poncelet C, Fauvet R, Boccara Jet al. Recurrence after cystectomy for borderline ovarian tumors: Results of a French multicenter study. Ann Surg Oncol 2006; 13: 565-571
177. Yinon Y, Beiner ME, Gotlieb WH et al. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline tumors. Fertil Steril 2007; 88: 479-484
178. Fauvet R, Poncelet C, Boccara Jet al. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 2005; 83: 284-290 (Pubitemid 40221778)
179. Kehoe S, Powell J. Long-term follow-up of women with borderline ovarian tumors. Int J Gynaecol Obstet 1996; 53: 139-143
180. Beiner ME, Gotlieb WH, Davidson B et al. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001; 92: 320-325
181. Borgfeldt C, Iosif C, MasbaeckA. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Rep Biol 2007; 134:110-114
182. Salomon LJ, Lhomme C, Pautier P et al. Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril 2006; 85: 1510.e1-4
183. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer 2006;42:149-158
184. du Bois A, Reuss A, Pujade-Lauraine E et al. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologi- sche Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 115: 1234-1244
185. Winter III WE, Maywell GL, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2008; 26: 83-89
186. Winter III WE, Maxwell GL, Tian CT et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 3621-3627
187. Tinelli R, Tineli A, Tinelli FG et al. Conservative surgery for borderline ovarian tumors: A review. Gynecol Oncol 2006; 100: 185-191
188. Park J-Y, Bae J, Lim MC et al. Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. Int JGynecol Oncol 2008; 18: 1202-1209
189. Obermair A, Hiebl S. Laparoscopy in the treatment ofovarian tumours of low malignant potential. Aust NZ J Obstet Gynaecol 2007; 47:438-444
190. Zivanovic O, Sonoda Y, Diaz JP et al. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol 2008; 111: 431-437
191. Ramirez PT, Frumovitz M, Wolf JK et al. Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer 2004; 14: 1070-1077
192. Vergote I, Marquette S, Amant F et al. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. IntJGynecol Cancer 2005; 15: 776-779
193. Huang K-G, Wang C-J, Chang T-C et al. Management of port-site metastasis after laparoscopic surgery for ovarian cancer. Obstet Gynecol 2003; 189: 16-21
194. Morice P, Camatte S, Larregain-Fournier D et al. Port-site implantation after laparoscopic treatment of borderline ovarian tumors. Obstet Gynecol 2004; 104:1167-1170
195. Havrilesky LJ, Peterson BL, Dryden DK et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol 2003; 102: 243-251
196. Sainz de la Cuesta RS, Goff BA, Fuller AF et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84: 1-7
197. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet2001; 375: 176-182
198. Medeiros LR, Stein AT, Fachel J et al. Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and metaanalysis. Int J Gynecol Cancer 2008; 18: 387-399
199. Brown Jones M. Borderline ovarian tumors: Current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 2006; 49: 517-525
200. Barnhill D, Heller P, Brzozowski P et al. Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 1985; 65: 53-59
201. Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: A systematic review. Eur J Obstet Gynecol 2007; 135:3-7
202. Attar E, Berkman S, Topuz S et al. Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: Case report. Human Reproduction 2004; 19:1472-1475
203. Hoffman JS, Laird L, Benadiva C et al. Case Report: In vitro fertilization following conservative management of stage 3 serous borderline tumor of the ovary. Gynecol Oncol 1999; 74: 515-518
204. Mantzavinos T, Kanakas N, Genatas C et al. Five years' follow-up in the two patients with borderline tumours of the ovary hyperstimulated by gonadotrophin therapy for in-vitro fertilization. Human Reproduction 1994; 9: 2032-2033
205. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009; 360: 902-911
206. Fain-Kahn V, Poirot C, Uzan C et al. Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod 2009; 1: 1-6
207. Crispens MA. Borderline ovarian tumours: a review of the recent literature. Cur Opin Obstet Gynecol 2003; 15: 39-48
208. Ortiz BH, Ailawadi M, Colitti C et al. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 2001; 61: 7264-7267
209. Emerson RE, Wang M, Liu F et al. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol 2007; 26: 387-394
210. Gu J, Roth LM, Younger C et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001; 93: 1147-1152
211. Bouchardy C, Ernandez S, Merglen A et al. Increased risk of second cancer among patients with ovarian borderline tumors. Gynecol Oncol 2008; 109: 210-214
212. Crispens MA, Bodurka D, Deavers M et al. Response and survival in patients with progressive or recurrent serous tumors of low malignant potential. Obstet Gynecol 2002; 99: 3-10
213. Genadry R, Poliakoff S, Rotmensch J et al. Primary, papillary peritoneal neoplasia. ObstetGynecol 1981; 58: 730-734
214. Russel P, Merkur H. Proliferating ovarian "epithelial" tumours: A clinico-pathological analysis of 144 cases. Aust N Z J Obstet Gynaec 1979; 19:45-51
215. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 2008; 10: 519-523